{"entity":{"id":"nct07483554","kind":"trial","name":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 2 trial of IBI343, Gemcitabine in pancreatic ductal adenocarcinoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors is a phase 2 interventional study registered as NCT07483554 by Innovent Biologics (Suzhou) Co. Ltd., with 389 participants planned, started 2026-04-20 and due to reach its primary completion in 2028-03-31. Interventions recorded: IBI343,Gemcitabine, Albumin-bound Paclitaxel. Conditions listed: CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07483554","url":"https://clinicaltrials.gov/study/NCT07483554"}],"tags":["ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["ibi343","gemcitabine"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07483554","phase":"2","setting":"A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of IBI343 in Combination Therapy for Patients With Advanced Malignant Solid Tumors.","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","participation":[{"nct":"NCT07483554","source":"https://clinicaltrials.gov/study/NCT07483554","fetchedAt":"2026-10-07T16:55:46.774Z","studySha256":"f2b4d4965475fec10533c1af481016883994ce5bf72cd37c4b1b7b921e320e40","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-03","leadSponsor":"Innovent Biologics (Suzhou) Co. Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":389,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-04-20","startedType":"actual","enrolled":389,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07483554/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}]}}